";s:4:"text";s:5513:"Specify what you have done since our inspection to correct your deviations and to prevent their recurrence. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. We remind you that common industry practice may not always be consistent with CGMP requirements and that you are responsible for the quality of drugs you produce.Your response does not describe sufficient corrective actions to ensure that your firm has adequate change management procedures in place: (1) to thoroughly evaluate your API manufacturing processes, including changes to those processes; and (2) to detect any unsafe impurities, including potentially mutagenic impurities. In addition, provide a retrospective review of all distributed batches within expiry to determine if your firm released batches that did not conform to established specifications or appropriate manufacturing standards.Your firm received a customer complaint on September 13, 2016, concerning Your response also states that in August 2017 you implemented a new • A revised complaint handling procedure and details of any further controls your facility has implemented to ensure that all complaints are adequately documented and thoroughly investigated.• Procedures for accepting and reprocessing returned drugs.In November 2011 you approved a valsartan API process change (PCRC - 11025) that included the use of the solvent You also failed to evaluate the need for additional analytical methods to ensure that unanticipated impurities were appropriately detected and controlled in your valsartan API before you approved the process change. FDA has not announced additional product recalls other than those already in place for … It does not create or confer any rights for or on any person, and does not operate to bind FDA or the public). 1 Branch No. Your firm’s executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance.Your firm’s quality systems are inadequate.
It is available on its own or in combination with other The review of valsartan medicines was triggered by the European Commission on 5 July 2018 under Based upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations and assist your firm in meeting CGMP requirements. Your investigation (DCE-18001) determined that the presence of NDMA was caused by the convergence of three process-related factors, one factor being the use of the solvent However, FDA analyses of samples of your API, and finished drug product manufactured with your API, identified NDMA in multiple batches manufactured with a different process, namely the • To include other factors that may have contributed to the presence of NDMA. The United Kingdom (UK) withdrew from the European Union (EU) on 31 January 2020 and is no longer an EU Member State.